IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the brain imaging analytics company, has presented research suggesting that reducing differences between MRI scanners does not always make it easier to track Huntington's disease. The work was shown at the European…
Key Highlights from the Publication Introduction of a computational model capable of predicting the impact of SI-targeted therapies in HD across a spectrum of inherited CAG-repeat lengths and potential ages of therapeutic intervention. Quantitative correlations that link levels of MSH3 knockdown…
Newswise — NEW YORK, Oct. 28, 2026 -- The Huntington's Disease Foundation (HDF) has awarded $2 million for its 2026 Transformative Research Awards (TRAs) to support two exceptional research collaborations with the potential to advance treatments for Huntington's disease (HD). Made possible by the support of…
Using genetic engineering technology, a team of scientists has established a pig model of Huntington's disease (HD), an inherited neurodegenerative disease. The researchers anticipate that the pigs could be a practical way to test treatments for HD, which is caused…
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease October 26, 2026 10:00 AM EDTCompany... Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease October 26, 2026 10:00 AM EDT Joshua Brodsky - Vice President of Investor Relations Hello,…
May 20, 2014, 08:30 ET With support from the Griffin Foundation in Washington, D.C., and in partnership with MedStar Georgetown and The Huntington's Disease Society of America, the British-based Huntington Disease Youth Organization (HDYO) has opened its first U.S. office at MedStar Georgetown. "HDYO will…
Alnylam is eyeing a pivotal trial for a Huntington’s disease drug after an early-stage clinical study showed “robust” reductions in the key huntingtin protein that is known to drive the difficult neurodegenerative disease. If the therapy is ultimately approved, Alnylam…
Alnylam reports phase 1b brezosiran data showing up to 83% mutant huntingtin reduction in Huntington's disease. Read more here. - Alnylam Pharmaceuticals (ALNY) said that phase 1b data for Huntington's disease candidate brezosiran (ALN-HTT02) showed a mean reduction of cerebrospinal fluid mutant huntingtin of…
SAN DIEGO — Patients with Huntington’s disease with chorea experienced improvements through 5 years of treatment with valbenazine, according to a poster presented at the 151st Annual Meeting of the American Neurological Association. “This is essentially our final data readout from the KINECT-HD…
By Jason Mast and Elaine Chen An experimental Huntington’s drug from Alnylam Pharmaceuticals showed promise in a small study, the company said Friday, suggesting it can partially silence the mutant gene that drives the devastating neurological disorder. Patients who received…
Huntington's disease: the AMT-130 gene-therapy result, research on slowing the disease, and families living with it.
An article joins this feed when it matches these terms. Each one is also a search of its own.